As a clinical-stage biotechnology company, bluebird bio is all geared up in the quest to find novel therapeutics for unmet areas in medicine. It seeks to develop next-generation products that would transform and change the lives of patients who are suffering from orphan diseases, like haemophilia B, retinal diseases and chronic lymphocytic leukemia. LentiGlobin and Lenti-D are the two flagship product candidates of the company that are currently in different phases of studies. The former is created as a treatment for beta-thalassemia, while the latter is for childhood cerebral adrenoleukodystrophy.
bluebird bio, Inc. was formerly known as Genetix Pharmaceuticals. It was in September 2010 that the company adopted its current name (written in small letters). The business is headquartered in Cambridge, Massachusetts and is publicly traded on the NASDAQ.